IR-Med
Development-stage medical device company utilizing infrared spectroscopy and AI for noninvasive point-of-care diagnostic devices, with first product PressureSafe for early detection of pressure injuries.
- CEO / Founder
- Ran Ziskind
- Team Size
- 1-10
- Stage
- Early Stage
- Total Funding
- $5.4M
- Latest Round
- Seed
Technology & Products
Key Products
PressureSafe (handheld optical monitoring device)
Technological Advantage
Proprietary spectrographic AI platform enables noninvasive detection and monitoring of subcutaneous tissue, with clinical studies showing 90% accuracy in US-Israel trials. The technology is protected by patents, providing a defensible position in the medical diagnostics space.
Differentiation
Value Proposition
Provides noninvasive, real-time detection and monitoring of biomarkers and molecules, enabling early intervention and improved patient outcomes, reducing healthcare costs associated with late-stage pressure injuries.
How They Differentiate
IR-Med's platform uses infrared spectroscopy combined with AI for noninvasive, real-time biomarker analysis, differentiating from competitors that may rely on invasive methods or lack AI integration.
Market & Competition
Target Customers
Healthcare professionals, hospitals, clinics
Industry Verticals
Healthcare; Medical Devices
Competitors
STRATA Skin Sciences; Escalon Medical; GlucoTrack; ENvue Medical
Growth & Milestones
Growth Metrics
Received $500,000 grant from Israel Innovation Authority; received ILS 644,551 (approx. $171,468) advance payment from IIA in April 2025.
Major Milestones
Granted patent in Israel for AI-driven platform; Achieved 90% accuracy in US-Israel clinical studies; Appointed Ran Ziskind as CEO in September 2024